Phaseline

Companies › InnoPharmax

InnoPharmax: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
D07001-Softgel Capsules
Gemcitabine, a nucleoside analog
RRM1, RRM2Phase 3Biliary Tract Cancer (BTC); Biliary Tract CancerDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05065957D07001-Softgel CapsulesPhase 2Biliary Tract CancerOncologyJul 2025
NCT06622057D07001-Softgel CapsulesPhase 3Biliary Tract Cancer (BTC)OncologyDec 2028

Targets

RRM1 (1) RRM2 (1)

Companies with the same targets

Theravia Beijing Immunochina Medical Science & Technology Jiangsu Healthy Life Innovation Medical Technology Jiangsu Hansoh Pharmaceutical

Companies built like this

Theravia Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.